An observational study in Hip Osteoarthritis, Hip Arthropathy and Hip Arthritis, sponsored by EUROS. Active, not recruiting at 9 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by EUROS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Osteoarthritis, Hip with a site in France — 10 open to participants now, 16 under way, none of them phase 3. Osteoarthritis, Hip · France.
Among the 38 studies in Osteoarthritis, Hip with a site in France, this one is the 15th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2021, is one of 17 observational ones, reaches primary completion later than 2 of the 15 other live ones, and was the 24th registered.
642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
Browse Osteoarthritis, Hip studies →10 of the 38 studies in Osteoarthritis, Hip with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Medacta International SA · Sites in France
Ages 18–85
Aptissen SA · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Lille Catholic University · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 131 is close to the median of 135 across 158 observational studies indexed under Osteoarthritis, Hip.
Median enrollment 130 across the 20 interventional studies, 250 across the 17 observational. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
EUROS is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
EUROS has 3 studies filed under Osteoarthritis, Hip — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis, Hip with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
| NCT05829733Aptissen SA6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis | 2027-04 |
| NCT06258369Lille Catholic UniversityGait Initiation and Transition From Double to Single Support in Patients With Unilateral Primary Coxarthrosis | 2027-08-19 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Osteoarthritis, Hip with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
EUROSSTEM is intended for use in primary and revision total hip replacement surgery.
Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components.
As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety
Post market observational study. This study is multicenter, prospective, non comparative.
Patient who fulfill the criteria of eligilibilty according to the instructions for use of EUROSTEM
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)
Device: hip arthroplasty
Hip prosthesis surgery
Safety of EUROSTEM Femoral Stem
Collect the safety of the device trought complications occurence rate
Time frame: 1 year
Radiological performances of EUROSTEM Femoral Stem
Collect the performances of the device trought radiological evaluation
Time frame: 1 year
Clinical performances of EUROSTEM Femoral Stem
Collect the performances of the device trought clinical scores
Time frame: 1 year
Survival of EUROSTEM Femoral Stem
Assess the survival rate of the device
Time frame: 10 year
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in Nov 2022, 17 months.
Of 81 observational studies under Osteoarthritis, Hip, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 113. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EUROS